[go: up one dir, main page]

US20020049323A1 - 1,2-Dihydro-2-oxoquinoline derivatives - Google Patents

1,2-Dihydro-2-oxoquinoline derivatives Download PDF

Info

Publication number
US20020049323A1
US20020049323A1 US09/829,203 US82920301A US2002049323A1 US 20020049323 A1 US20020049323 A1 US 20020049323A1 US 82920301 A US82920301 A US 82920301A US 2002049323 A1 US2002049323 A1 US 2002049323A1
Authority
US
United States
Prior art keywords
group
hex
dihydro
atom
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/829,203
Other versions
US6380384B1 (en
Inventor
Atsuro Nakazato
Taketoshi Okubo
Toshihito Kumagai
Shigeyuki Chaki
Kazuyuki Tomisawa
Masashi Nagamine
Makoto Gotoh
Masanori Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/829,203 priority Critical patent/US6380384B1/en
Publication of US20020049323A1 publication Critical patent/US20020049323A1/en
Application granted granted Critical
Publication of US6380384B1 publication Critical patent/US6380384B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Definitions

  • the present invention relates to compounds having a high affinity for mitochondrial diazepam binding inhibitor receptor (MDR).
  • MDR mitochondrial diazepam binding inhibitor receptor
  • Benzodiazepine (BZ) receptors which are an acting site of anti-anxiety drugs are classified into 2 subtypes of central benzodiazepine receptor (CBR) located on GABA A receptor/chloride channel complex and MDR located on the central nervous system (glial cells) or adrenal glands (Clin. Neuropharmacol., 16, 401-417 (1993)).
  • CBR central benzodiazepine receptor
  • MDR located on the central nervous system (glial cells) or adrenal glands
  • CBR agonists of which representative is diazepam are widely used as anti-anxiety drugs.
  • CBR agonists act directly on GABA A receptor/chloride channel complex, they cause an anti-anxiety action together with side-effects such as excessive sedation or psychic dependence.
  • MDR agonists act indirectly on GABA A receptor/chloride channel complex via synthesis of neurosteroids such as endogenous neuroactive steroids (endogenous anti-anxiety substances), they cause an anti-anxiety action, but do not cause side-effects such as psychic dependence or excessive sedation (J. Pharmacol. Exp. Ther., 267, 462-471, 1993; ibid., 265, 649-656, 1993).
  • the compounds which act on MDR have a possibility of use as therapeutical agents of sleeping disorders, epilepsy, dyskinesia accompanied by muscle rigidity, feeding disorders, circulation disorders, recognition and learning disability or drug dependence (Progress in Neurobiology, 38, 379-395, 1992, ibid., 49, 73-97, 1996; J. Neurochem., 58, 1589-1601; Neuropharmacol., 30, 1435-1440, 1991).
  • these compounds in view of the physiological functions of MDR, have a possibility of use as therapeutic agents of cancer (Biochimica et Biophysica Acta, 1241, 453-470, 1995), lipid metabolism abnormality (Eur. J.
  • the present invention is directed to a 1,2-dihydro-2-oxoquinoline derivative represented by Formula [I]:
  • Ar is a pyridyl group or a group represented by the formula:
  • X 3 and X 4 are the same or different, and are each a hydrogen atom, a halogen atom, a C 1-5 alkyl group, a C 1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group
  • Y is a nitrogen atom or CH
  • R 1 and R 2 are the same or different, and are each a hydrogen atom, a C 1-10 alkyl group, a C 3-15 alkoxyalkyl group or a C 3-15 alkylaminoalkyl group, or R 1 and R 2 taken together with the nitrogen atom to which they are attached form a cyclic amino group
  • X 1 and X 2 are the same or different, and are each a hydrogen atom, a C 1-5 alkyl group, a C 1-5 alkoxy group or a halogen atom, or X 1 and X 2 taken together form an alkylenedioxy group
  • n is an integer of 1 to 3, provided that Y is other
  • the halogen atom for X 3 and X 4 refers to a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • the C 1-5 alkyl group for X 3 and X 4 refers to a straight or branched alkyl group, and examples thereof are a methyl group, an ethyl group, a propyl group and an isopropyl group.
  • the C 1-5 alkoxy group for X 3 and X 4 refers to a straight or branched alkoxy group, and examples thereof are a methoxy group and an ethoxy group.
  • the C 1-10 alkyl group for R 1 and R 2 refers to a straight, branched or cyclic alkyl group, and examples thereof are a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a butyl group, an isobutyl group, a cyclobutyl group, a cyclopropylmethyl group, a pentyl group, an isopentyl group, a cyclopentyl group, a cyclobutylmethyl group, a 1-ethylpropyl group, a hexyl group, an isohexyl group, a cyclohexyl group, a cyclopentylmethyl group, a 1-ethylbutyl group, a heptyl group, an isoheptyl group, a cyclohexylmethyl group, an octyl group, a
  • the C 3-15 alkoxyalkyl group for R 1 and R 2 refers to a straight, branched or cyclic C 1-13 alkoxy-C 2-14 alkyl group, and examples thereof are a methoxyethyl group, a methoxypropyl group, a methoxybutyl group, an ethoxyethyl group, an ethoxypropyl group, an ethoxybutyl group, an ethoxypentyl group, an ethoxyhexyl group, an ethoxyheptyl group, a propoxyethyl group, a propoxypropyl group, a propoxybutyl group, an isopropoxyethyl group and a cyclopropylmethoxyethyl group.
  • the C 3-15 alkylaminoalkyl group for R 1 and R 2 refers to a straight, branched or cyclic C 1-13 alkylamino-C 2-14 alkyl group, and examples thereof are a methylaminoethyl group, a dimethylaminoethyl group, a methylaminopropyl group, a dimethylaminopropyl group, a methylaminobutyl group, an ethylaminoethyl group, an ethylaminopropyl group, an ethylaminobutyl group, an ethylaminopentyl group, an ethylaminohexyl group, an ethylaminoheptyl group, an ethylaminooctyl group, a propylaminoethyl group, a propylaminopropyl group, a propylaminobutyl group, an isopropy
  • Examples of the cyclic amino group which is formed by R 1 , R 2 and the nitrogen atom to which they are attached are a pyrrolidino group, a piperidino group, a homopiperidino group, a morpholino group, a piperazino group, an N-methylpiperazino group and a 3,5-dimethylpiperazino group.
  • the C 1-5 alkyl group for X 1 and X 2 refers to a straight, branched or cyclic alkyl group, and examples thereof are a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group and a pentyl group.
  • the C 1-5 alkoxy group for X 1 and X 2 refers to a straight, branched or cyclic alkoxy group, and examples thereof are a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a cyclopropylmethoxy group, a pentoxy group and an isopentoxy group.
  • the halogen atom for X 1 and X 2 refers to a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • Examples of the C 1-5 alkylenedioxy group which is formed by X 1 and X 2 taken together are a methylenedioxy group, an ethylenedioxy group and an n-propylenedioxy group.
  • examples of the pharmaceutically acceptable salt in the present invention are salts with mineral acids such as sulfuric acid, hydrochloric acid or phosphoric acid, or salts with organic acids such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, methanesulfonic acid or benzenesulfonic acid.
  • the compound of Formula [I] can be prepared by the following general preparation methods 1 to 3.
  • Ar, Y, R 1 , R 2 , X 1 , X 2 and n are as defined above, Y 1 is a nitrogen atom or CH, R 3 and R 4 are the same or different, and are each a C 1-5 alkyl group or a benzyl group, and X 5 is a chlorine atom, a bromine atom or an iodine atom.
  • Examples of the inert solvent are alcohols (e.g. methanol or ethanol), ethers (e.g. 1,2-dimethoxyethane or tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile, N,N-dimethylformamide, water and a mixture thereof.
  • Examples of the phase transfer catalyst are quaternary ammonium salts (e.g. benzyltriethyl ammonium bromide) and crown ethers (e.g. 18-crown-6-ether).
  • Examples of the base are inorganic bases (e.g. potassium carbonate, sodium hydroxide, sodium hydride or metallic sodium) and alcoholates (e.g. potassium t-butoxide or sodium ethoxide).
  • Examples of the inert solvent are alcohols (e.g. methanol or ethanol), ketones (e.g. acetone), ethers (e.g. 1,2-dimethoxyethane or tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile, N,N-dimethylformamide and a mixture of these solvents with water.
  • Examples of the base are inorganic bases (e.g. potassium carbonate, sodium carbonate, potassium hydroxide or sodium hydroxide).
  • Examples of the acid are hydrochloric acid, sulfuric acid and phosphoric acid.
  • Step (C): The compound (6) of the present invention can be synthesized from the 1-arylalkyl-1,2-dihydro-2-oxoquinolinecarboxylic acid derivative (4) via the acid halide or mixed acid anhydride thereof.
  • the acid halide includes an acid chloride and an acid bromide, and for example, they can be obtained by reacting a halogenating agent (e.g. thionyl chloride, thionyl bromide, oxalyl chloride, carbon tetrachloride-triphenylphosphine or carbon tetrabromide-triphenylphosphine) in an inert solvent.
  • a halogenating agent e.g. thionyl chloride, thionyl bromide, oxalyl chloride, carbon tetrachloride-triphenylphosphine or carbon tetrabromide-triphenylphosphine
  • an inert solvent examples include ethers (e.g. tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), aceton
  • the mixed acid anhydride includes an anhydride of a carboxylic acid with a carbonic acid, and for example, it can be obtained by reacting a halocarbonate ester (e.g. ethyl chlorocarbonate or isobutyl chlorocarbonate) in the presence of an organic base (e.g. triethylamine, diisopropylethylamine, N-methylmorpholine or pyridine) or an inorganic base (e.g. sodium hydride) in an inert solvent.
  • organic base e.g. triethylamine, diisopropylethylamine, N-methylmorpholine or pyridine
  • an inorganic base e.g. sodium hydride
  • the inert solvent are ethers (e.g. tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), ace
  • the compound (6) of the present invention can be also obtained by the reaction of the 1-arylalkyl-1,2-dihydro-2-oxoquinolinecarboxylic acid derivative together with a condensing agent and an amine (5) in an inert solvent.
  • the condensing agent refers to a conventional amidating reagent such as, for example, diphenylphosphoryl azide, diethyl cyanophosphate, carbonyldiimidazole or carbodiimides of which representatives are N,N′-dicyclohexylcarbodiimide and N-ethyl-N′-dimethylaminopropylcarbodiimide hydrochloride.
  • the inert solvent are ethers (e.g. 1,2-dimethoxyethane or tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g.
  • N-hydroxysuccinimide 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine, etc. can be added as an activating agent.
  • a 1,2-dihydro-2-oxoquinolinecarboxylic acid derivative (7) is amidated according to Step (C) to give a compound (8) of the present invention, which is then subjected to 1-arylalkylation according to Step (A) to give a compound (6) of the present invention.
  • the inert solvent examples include alcohols (e.g. methanol or ethanol), ethers (e.g.-1,2-dimethoxyethane or tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile, N,N-dimethylformamide, water and a mixture thereof.
  • the base includes inorganic bases (e.g. potassium carbonate, sodium hydroxide, sodium hydride or metallic sodium) or alcoholates (e.g. potassium t-butoxide or sodium ethoxide).
  • inert solvent examples include alcohols (e.g. methanol or ethanol), ethers (e.g. 1,2-dimethoxyethane or tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile, N,N-dimethylformamide, water and a mixture thereof.
  • alcohols e.g. methanol or ethanol
  • ethers e.g. 1,2-dimethoxyethane or tetrahydrofuran
  • hydrocarbons e.g. toluene or benzene
  • halogenide solvents e.g. chloroform or dichloromethane
  • the compounds of the present invention have a high affinity for MDR, and therefore they are useful as therapeutic or preventive drugs of central diseases such as anxiety, related diseases thereto, depression, epilepsy, sleeping disorders, recognition and learning disability or schizophrenia, dyskinesia accompanied by muscle rigidity, feeding disorders, circulation disorders, drug dependence, cancer, lipid metabolism abnormality, cerebral infarction, AIDS, Alzheimer's disease or Huntington chorea.
  • central diseases such as anxiety, related diseases thereto, depression, epilepsy, sleeping disorders, recognition and learning disability or schizophrenia, dyskinesia accompanied by muscle rigidity, feeding disorders, circulation disorders, drug dependence, cancer, lipid metabolism abnormality, cerebral infarction, AIDS, Alzheimer's disease or Huntington chorea.
  • the reaction mixture was concentrated under reduced pressure, and the residue, after addition of ethyl acetate, was washed with water, IN hydrochloric acid, a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. After removal of the drying agent by filtration, the filtrate was concentrated under reduced pressure.
  • the aqueous phase was made acidic with 1 N hydrochlorid acid, and extracted with ethyl acetate.
  • the organic phase was washed with a saturated aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate. After removal of the drying agent by filtration, the filtrate was concentrated under reduced pressure. The residue was crystallized from ethanol to give 5.88 g of ethyl 1-benzyl-4-hydroxy-1,2-dihydro-2-oxoquinoline-3-carboxylate.
  • a binding assay using the [ 3 H]-labeled ligand was carried out according to the following method as described in Journal of Pharmacology and Experimental Therapeutics, 262, 971(1992).
  • Rat cerebral cortex was homogenized using a Teflon-coated homogenizer in a 10 mM HEPES buffer (pH 7.4) containing 0.32 M sucrose in ten volumes of the wet weight.
  • the homogenate was centrifuged at 900 ⁇ g for 10 minutes, and the resulting supernatant was centrifuged at 9,000 ⁇ g for 10 minutes.
  • the precipitate was suspended in a HEPES buffer to give a protein concentration of 1 mg/ml, and centrifuged at 12,000 ⁇ g for 10 minutes.
  • the resulting precipitate was suspended in a 50 mM HEPES buffer (pH 7.4) to give a crude mitochondria fraction.
  • MDR Binding Assay Mitochondria sample (1.0 mg protein/ml), [ 3 H]PK11195 (2 nM) and the test drug were reacted at 4° C. for 90 minutes.
  • reaction mixture was filtered with suction through a glass filter (GF/B) treated with 0.3% polyethyleneimine, and the radioactivity on the filter was measured by a liquid scintillation spectrometer.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A 1,2-dihydro-2-oxoquinoline derivative represented by the formula:
Figure US20020049323A1-20020425-C00001
wherein Ar is a pyridyl group or a group represented by the formula:
Figure US20020049323A1-20020425-C00002
(wherein X3 and X4 are the same or different, and are each a hydrogen atom, a halogen atom, a C1-5 alkyl group, a C1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom, CH or C(OH), R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom, or X1 and X2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof.

Description

    TECHNICAL FIELD
  • The present invention relates to compounds having a high affinity for mitochondrial diazepam binding inhibitor receptor (MDR). [0001]
    • BACKGROUND ART
  • Benzodiazepine (BZ) receptors which are an acting site of anti-anxiety drugs are classified into 2 subtypes of central benzodiazepine receptor (CBR) located on GABA[0002] A receptor/chloride channel complex and MDR located on the central nervous system (glial cells) or adrenal glands (Clin. Neuropharmacol., 16, 401-417 (1993)). Recently, CBR agonists of which representative is diazepam are widely used as anti-anxiety drugs. However, since CBR agonists act directly on GABAA receptor/chloride channel complex, they cause an anti-anxiety action together with side-effects such as excessive sedation or psychic dependence. On the other hand, since MDR agonists act indirectly on GABAA receptor/chloride channel complex via synthesis of neurosteroids such as endogenous neuroactive steroids (endogenous anti-anxiety substances), they cause an anti-anxiety action, but do not cause side-effects such as psychic dependence or excessive sedation (J. Pharmacol. Exp. Ther., 267, 462-471, 1993; ibid., 265, 649-656, 1993).
  • Accordingly, there is a need of the development of therapeutic agents for diseases (obsessive disorders, panic disorders) on which the previous BZs do not have a satisfactorily therapeutic effect, and development of MDR agonists as anti-anxiety drugs which alleviate the side-effects as recognized in the previous BZs. [0003]
  • Furthermore, the compounds which act on MDR, in view of acting on GABA[0004] A receptors, have a possibility of use as therapeutical agents of sleeping disorders, epilepsy, dyskinesia accompanied by muscle rigidity, feeding disorders, circulation disorders, recognition and learning disability or drug dependence (Progress in Neurobiology, 38, 379-395, 1992, ibid., 49, 73-97, 1996; J. Neurochem., 58, 1589-1601; Neuropharmacol., 30, 1435-1440, 1991). In addition, these compounds, in view of the physiological functions of MDR, have a possibility of use as therapeutic agents of cancer (Biochimica et Biophysica Acta, 1241, 453-470, 1995), lipid metabolism abnormality (Eur. J. Pharmacol., 294, 601-607, 1995), schizophrenia (Neuropharmacology, 35, 1075-1079, 1996), cerebral infarction (J. Neurosci., 15, 5263-5274, 1995), AIDS (Abstracts of the fifth international conference on AIDS, p. 458, 1989), Alzheimer's disease (Alzheimer Dis. Assoc. Disotd., 2, 331-336, 1988) or Huntington chorea (Brain Res., 248, 396-401, 1982).
  • Among the compounds having affinity for MDR, there are indole compounds disclosed in Japanese Translation of PCT publication (Kohyo) No. 6-501030. [0005]
    • DISCLOSURE OF THE INVENTION
  • As a result of extensive researches about compounds having a high affinity for MDR, the present inventors have, found that the specific 1,2-dihydro-2-oxoquinoline derivatives meet the above object, thus the present invention has been accomplished. As stated above, while the indole compounds having an affinity for MDR are known, there are not reported 1,2-dihydro-2-oxoquinoline derivatives of the present invention which have an affinity for MDR. [0006]
  • The present invention is directed to a 1,2-dihydro-2-oxoquinoline derivative represented by Formula [I]: [0007]
    Figure US20020049323A1-20020425-C00003
  • wherein Ar is a pyridyl group or a group represented by the formula: [0008]
    Figure US20020049323A1-20020425-C00004
  • (wherein X[0009] 3 and X4 are the same or different, and are each a hydrogen atom, a halogen atom, a C1-5 alkyl group, a C1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom or CH, R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom, or X1 and X2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3, provided that Y is other than CH when all of R1, R2, X1, X2, X3 and X4 are hydrogen atoms; or a pharmaceutically acceptable salt thereof.
  • In the present invention, the halogen atom for X[0010] 3 and X4 refers to a fluorine atom, a chlorine atom, a bromine atom or an iodine atom. The C1-5 alkyl group for X3 and X4 refers to a straight or branched alkyl group, and examples thereof are a methyl group, an ethyl group, a propyl group and an isopropyl group. The C1-5 alkoxy group for X3 and X4 refers to a straight or branched alkoxy group, and examples thereof are a methoxy group and an ethoxy group. The C1-10 alkyl group for R1 and R2 refers to a straight, branched or cyclic alkyl group, and examples thereof are a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a butyl group, an isobutyl group, a cyclobutyl group, a cyclopropylmethyl group, a pentyl group, an isopentyl group, a cyclopentyl group, a cyclobutylmethyl group, a 1-ethylpropyl group, a hexyl group, an isohexyl group, a cyclohexyl group, a cyclopentylmethyl group, a 1-ethylbutyl group, a heptyl group, an isoheptyl group, a cyclohexylmethyl group, an octyl group, a nonyl group and a decyl group. The C3-15 alkoxyalkyl group for R1 and R2 refers to a straight, branched or cyclic C1-13 alkoxy-C2-14 alkyl group, and examples thereof are a methoxyethyl group, a methoxypropyl group, a methoxybutyl group, an ethoxyethyl group, an ethoxypropyl group, an ethoxybutyl group, an ethoxypentyl group, an ethoxyhexyl group, an ethoxyheptyl group, a propoxyethyl group, a propoxypropyl group, a propoxybutyl group, an isopropoxyethyl group and a cyclopropylmethoxyethyl group. The C3-15 alkylaminoalkyl group for R1 and R2 refers to a straight, branched or cyclic C1-13 alkylamino-C2-14 alkyl group, and examples thereof are a methylaminoethyl group, a dimethylaminoethyl group, a methylaminopropyl group, a dimethylaminopropyl group, a methylaminobutyl group, an ethylaminoethyl group, an ethylaminopropyl group, an ethylaminobutyl group, an ethylaminopentyl group, an ethylaminohexyl group, an ethylaminoheptyl group, an ethylaminooctyl group, a propylaminoethyl group, a propylaminopropyl group, a propylaminobutyl group, an isopropylaminoethyl group, a cyclopropylmethylaminoethyl group and a pyrrolidinoethyl group. Examples of the cyclic amino group which is formed by R1, R2 and the nitrogen atom to which they are attached are a pyrrolidino group, a piperidino group, a homopiperidino group, a morpholino group, a piperazino group, an N-methylpiperazino group and a 3,5-dimethylpiperazino group. The C1-5 alkyl group for X1 and X2 refers to a straight, branched or cyclic alkyl group, and examples thereof are a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group and a pentyl group. The C1-5 alkoxy group for X1 and X2 refers to a straight, branched or cyclic alkoxy group, and examples thereof are a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a cyclopropylmethoxy group, a pentoxy group and an isopentoxy group. The halogen atom for X1 and X2 refers to a fluorine atom, a chlorine atom, a bromine atom or an iodine atom. Examples of the C1-5 alkylenedioxy group which is formed by X1 and X2 taken together are a methylenedioxy group, an ethylenedioxy group and an n-propylenedioxy group. In addtion, examples of the pharmaceutically acceptable salt in the present invention are salts with mineral acids such as sulfuric acid, hydrochloric acid or phosphoric acid, or salts with organic acids such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, methanesulfonic acid or benzenesulfonic acid.
  • The compound of Formula [I] can be prepared by the following general preparation methods 1 to 3. In the following reaction formulae, Ar, Y, R[0011] 1, R2, X1, X2 and n are as defined above, Y1 is a nitrogen atom or CH, R3 and R4 are the same or different, and are each a C1-5 alkyl group or a benzyl group, and X5 is a chlorine atom, a bromine atom or an iodine atom.
    Figure US20020049323A1-20020425-C00005
  • Step (A): A 1,2-dihydro-2-oxoguinolinecarboxylate ester derivative (1) can be reacted with an arylalkyl halide derivative (2) in an inert solvent, if necessary, by using a phase transfer catalyst in the presence of a base to give a 1-arylalkyl-1,2-dihydro-2-oxoquinolinecarborboxylate ester derivative (3). [0012]
  • Examples of the inert solvent are alcohols (e.g. methanol or ethanol), ethers (e.g. 1,2-dimethoxyethane or tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile, N,N-dimethylformamide, water and a mixture thereof. Examples of the phase transfer catalyst are quaternary ammonium salts (e.g. benzyltriethyl ammonium bromide) and crown ethers (e.g. 18-crown-6-ether). Examples of the base are inorganic bases (e.g. potassium carbonate, sodium hydroxide, sodium hydride or metallic sodium) and alcoholates (e.g. potassium t-butoxide or sodium ethoxide). [0013]
  • Step (B): The 1-arylalkyl-1,2-dihydro-2-oxoquinolinecarborboxylate ester derivative (3) is hydrolyzed with a base or an acid in an inert solvent to give a 1-arylalkyl-1,2-dihydro-2-oxoquinolinecarboxylic acid derivative (4). [0014]
  • Examples of the inert solvent are alcohols (e.g. methanol or ethanol), ketones (e.g. acetone), ethers (e.g. 1,2-dimethoxyethane or tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile, N,N-dimethylformamide and a mixture of these solvents with water. Examples of the base are inorganic bases (e.g. potassium carbonate, sodium carbonate, potassium hydroxide or sodium hydroxide). Examples of the acid are hydrochloric acid, sulfuric acid and phosphoric acid. [0015]
  • Step (C): The compound (6) of the present invention can be synthesized from the 1-arylalkyl-1,2-dihydro-2-oxoquinolinecarboxylic acid derivative (4) via the acid halide or mixed acid anhydride thereof. [0016]
  • The acid halide includes an acid chloride and an acid bromide, and for example, they can be obtained by reacting a halogenating agent (e.g. thionyl chloride, thionyl bromide, oxalyl chloride, carbon tetrachloride-triphenylphosphine or carbon tetrabromide-triphenylphosphine) in an inert solvent. Examples of the above inert solvent are ethers (e.g. tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile and N,N-dimethylformamide. [0017]
  • The mixed acid anhydride includes an anhydride of a carboxylic acid with a carbonic acid, and for example, it can be obtained by reacting a halocarbonate ester (e.g. ethyl chlorocarbonate or isobutyl chlorocarbonate) in the presence of an organic base (e.g. triethylamine, diisopropylethylamine, N-methylmorpholine or pyridine) or an inorganic base (e.g. sodium hydride) in an inert solvent. Examples of the inert solvent are ethers (e.g. tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile and N,N-dimethylformamide. [0018]
  • The compound (6) of the present invention can be also obtained by the reaction of the 1-arylalkyl-1,2-dihydro-2-oxoquinolinecarboxylic acid derivative together with a condensing agent and an amine (5) in an inert solvent. [0019]
  • The condensing agent refers to a conventional amidating reagent such as, for example, diphenylphosphoryl azide, diethyl cyanophosphate, carbonyldiimidazole or carbodiimides of which representatives are N,N′-dicyclohexylcarbodiimide and N-ethyl-N′-dimethylaminopropylcarbodiimide hydrochloride. Examples of the inert solvent are ethers (e.g. 1,2-dimethoxyethane or tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile and N,N-dimethylformamide. In this reaction, if necessary, N-hydroxysuccinimide, 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine, etc. can be added as an activating agent. [0020]
    Figure US20020049323A1-20020425-C00006
  • A 1,2-dihydro-2-oxoquinolinecarboxylic acid derivative (7) is amidated according to Step (C) to give a compound (8) of the present invention, which is then subjected to 1-arylalkylation according to Step (A) to give a compound (6) of the present invention. [0021]
    Figure US20020049323A1-20020425-C00007
  • Step (D): An isatoic anhydride derivative (9) Is reacted with a malonate ester (10) in an inert solvent in the presence of a base to give a 4-hydroxy-1,2-dihydro-2-oxoquinolinecarboxylate ester derivative (11). [0022]
  • Examples of the inert solvent are alcohols (e.g. methanol or ethanol), ethers (e.g.-1,2-dimethoxyethane or tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile, N,N-dimethylformamide, water and a mixture thereof. The base includes inorganic bases (e.g. potassium carbonate, sodium hydroxide, sodium hydride or metallic sodium) or alcoholates (e.g. potassium t-butoxide or sodium ethoxide). [0023]
  • Step (E): The 4-hydroxy-1,2-dihydro-2-oxoquinolinecarboxylate ester derivative (11) can be reacted with an amine derivative (5) in an inert solvent to give a compound (12) of the present invention. [0024]
  • Examples of the inert solvent are alcohols (e.g. methanol or ethanol), ethers (e.g. 1,2-dimethoxyethane or tetrahydrofuran), hydrocarbons (e.g. toluene or benzene), halogenide solvents (e.g. chloroform or dichloromethane), acetonitrile, N,N-dimethylformamide, water and a mixture thereof. [0025]
    • INDUSTRIAL APPLICABILITY
  • The compounds of the present invention have a high affinity for MDR, and therefore they are useful as therapeutic or preventive drugs of central diseases such as anxiety, related diseases thereto, depression, epilepsy, sleeping disorders, recognition and learning disability or schizophrenia, dyskinesia accompanied by muscle rigidity, feeding disorders, circulation disorders, drug dependence, cancer, lipid metabolism abnormality, cerebral infarction, AIDS, Alzheimer's disease or Huntington chorea. [0026]
    • BEST MODE OF CARRYING OUT THE INVENTION
  • The present invention is illustrated in more detail by showing the following examples and an experiment.[0027]
    • EXAMPLE 1
  • (1) Preparation of N,N-dihexyl-1-benzyl-1,2-dihydro-2-oxoquinoxaline-3-carboxamide [0028]
  • A solution of 3.90 g of ethyl 1,2-dihydro-2-oxoquinoxaline-3-carboxylate in 25 ml of N,N-dimethylformamide was added dropwise to a suspension of 0.79 g of 60% sodium hydride/oil in 10 ml of N,N-dimethylformamide at room temperature over 30 minutes. After stirring at room temperature for 30 minutes, 3.36 g of benzyl bromide was added dropwise over 10 minutes, followed by stirring at room temperature overnight. The reaction mixture was concentrated under reduced pressure. The residue, after addition of ethyl acetate, was washed with water, 1 N hydrochloric acid, a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. After removal of the drying agent by filtration, the filtrate was concentrated under reduced pressure. The residue was purified by chromatography (silica gel; Wakogel C200 (manufactured by Wako Pure Chemicals), developing solvent; hexane-ethyl acetate=10:1-2:1) and recrystallized from ethyl acetate-hexane to give 3.77 g of ethyl 1-benzyl-1,2-dihydro-2-oxoquinoxaline-3-carboxylate. [0029]
  • (2) To 2.00 g of ethyl 1-benzyl-1,2-dihydro-2-oxoquinoxaline-3-carboxylate were added 10 ml of ethanol and 20 ml of 10% aqueous sodium hydroxide solution, followed by stirring at room temperature for an hour. To the reaction solution was added dropwise 3 N hydrochloric acid to make acidic (pH=3.0), and the precipitated crystals were collected by filtration and washed with water and diethyl ether to give 1.73 g of 1-benzyl-1,2-dihydro-2-oxoquinoxaline-3-carboxylic acid. [0030]
  • (3) In 30 ml of tetrahydrofuran were dissolved 0.50 g of 1-benzyl-1,2-dihydro-2-oxoquinoxaline-3-carboxylic acid and 0.87 ml of triethylamine, and after cooling to −40° C., 0.19 ml of ethyl chlorocarbonate was added dropwise over 5 minutes. After stirring at −40° C. for 10 minutes, 0.46 ml of dihexylamine was added dropwise over 5 minutes. After stirring at −40° C. for an hour, the temperature was raised to room temperature over an hour, followed by stirring at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the residue, after addition of ethyl acetate, was washed with water, IN hydrochloric acid, a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. After removal of the drying agent by filtration, the filtrate was concentrated under reduced pressure. The residue was purified by chromatography (silica gel; Wakogel C200 (manufactured by Wako Pure Chemicals), developing solvent; chloroform) and recrystallized from hexane to give 0.53 g of N,N-dihexyl-l-benzyl-1,2-dihydro-2-oxoquinoxaline-3-carboxamide. [0031]
  • The structures and physical property data of the present compound and the compounds prepared similarly are shown in Tables 1 and 2. [0032]
    • EXAMPLE 2
  • Preparation of N,N-dihexyl-1-(3-picolyl)-1,2-dihydro-2-oxoquinoline-3-carboxamide [0033]
  • (1) In a mixture of 50 ml of tetrahydrofuran and 250 ml of N,N-dimethylformamide were dissolved 9.46 g of 1,2-dihydro-2-oxoquinoline-3-carboxylic acid and 5.06 g of N-methylmorpholine, and after cooling to −15° C., 6.83 g of isobutyl chlorocarbonate was added dropwise over 10 minutes. After stirring at −15° C. for 10 minutes, 9.73 g of dihexylamine was added dropwise over 5 minutes. After stirring at −15° C. for 4 hours and then at room temperature overnight, the reaction mixture was concentrated under reduced pressure, and the residue, after addition of ethyl acetate, was washed with water, 1N hydrochloric acid, a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. After removal of the drying agent by filtration, the filtrate was concentrated under reduced pressure. The residue was recrystallized from hexane to give 13.51 g of N,N-dihexyl-1,2-dihydro-2-oxoquinoline-3-carboxamide. [0034]
  • (2) To a solution of 1.01 g of N,N-dihexyl-1,2-dihydro-2-oxoquinoline-3-carboxamide in 13 ml of N,N-dimethylformamide was added 136 mg of 60% sodium hydride/oil, followed by stirring at room temperature for an hour. To the reaction solution was added 434 mg of 3-picolyl chloride, followed by stirring at room temperature for 4 hours. The reaction mixture was poured into water and extracted with ethyl acetate, and the extract was washed with water, a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. After removal of the drying agent by filtration, the filtrate was concentrated under reduced pressure. The residue was purified by chromatography (silica gel; Wakogel C200 (manufactured by Wako Pure Chemicals), developing solvent; hexane-ethyl acetate=7:13-1:19) and recrystallized from ethyl acetate to give 0.47 g of N,N-dihexyl-1-(3-picolyl)-1,2-dihydro-2-oxoquinoline-3-carboxamide. [0035]
  • The structures and physical property data of the present compound and the compounds prepared similarly are shown in Tables 1 and 2. [0036]
    • EXAMPLE 3
  • Preparation of N,N-dihexyl-1-benzyl-4-hydroxy-1,2-dihydro-2-oxoquinoline-3-carboxamide [0037]
  • (1) In a solution of 4.50 g of diethyl malonate in 20 ml of N,N-dimethylformamide was gradually added 1.10 g of 62.4% sodium hydride at room temperature, and stirring was continued at room temperature until hydrogen evolution ceased. The reaction solution was heated to 80° C., and a solution of 6.70 g of N-benzylisatoic anhydride in 20 ml of N,N-dimethylformamide was added dropwise. After the addition, the reaction mixture was stirred under heating at 120° C. for 7 hours. After cooling to room temperature, the reaction mixture was poured into ice water and washed with ethyl acetate. The aqueous phase was made acidic with 1 N hydrochlorid acid, and extracted with ethyl acetate. The organic phase was washed with a saturated aqueous sodium chloride solution, and dried over anhydrous magnesium sulfate. After removal of the drying agent by filtration, the filtrate was concentrated under reduced pressure. The residue was crystallized from ethanol to give 5.88 g of ethyl 1-benzyl-4-hydroxy-1,2-dihydro-2-oxoquinoline-3-carboxylate. [0038]
  • (2) A mixture of 0.30 g of ethyl 1-benzyl-4-hydroxy-1,2-dihydro-2-oxoquinoline-3-carboxylate and 2 ml of dihexylamine was stirred under heating at 130° C. for 2 hours. After cooling to room temperature, to the reaction solution were added chloroform and 1 N hydrochloric acid, and the separated organic phase was washed with 1 N hydrochloric acid and water. The organic phase was dried over anhydrous magnesium sulfate. After removal of the drying agent by filtration, the filtrate was concentrated under reduced pressure. The residue was purified by chromatography ((silica gel; Merk silica gel 230-4000 mesh (Merk Co.), developing solvent; chloroform) and allowed to stand for crystallization to give 0.36 g of N,N-dihexyl-l-benzyl-4-hydroxy-1,2-dihydro-2-oxoquinoline-3-carboxamide. [0039]
  • The structures and physical property data of the present compound and the compounds prepared similarly are shown in Table 2. [0040]
    TABLE 1
    Figure US20020049323A1-20020425-C00008
    Comp.*1 Exp.*2 m.p. (Recry.sol.*3)
    No. No. R1 R2 X1 X2 Y n Ar (° C.)
    01 1 H H H H CH 1 Ph 229.0 ˜ 231.0 (CH2Cl2/Hex)
    02 1 Me H H H CH 1 Ph 177.0 ˜ 177.5 (AcOEt/Hex)
    03 1 Me Me H H CH 1 Ph 219.0 ˜ 220.0 (AcOEt)
    04 1 n-Pr n-Pr H H CH 1 Ph 135.0 ˜ 136.0 (AcOEt/Hex)
    05 1 n-Hex n-Hex H H CH 1 Ph 118.5 ˜ 120.0 (AcOEt/Hex)
    06 1 n-Dec n-Dec H H CH 1 Ph 78.5 ˜ 80.0 (AcOEt/Hex)
    07 1 (CH3)2N(CH2)3 (CH3)2N(CH2)3 H H CH 1 Ph 84.0 ˜ 86.0 (Hex)
    08 1 (CH2CHMe)2NH*4 H H CH 1 Ph 199.5 ˜ 201.0 (Hex)
    09 2 n-Hex n-Hex H H CH 1 2-F—Ph 93.0 ˜ 94.0 (standing*5)
    10 2 n-Hex n-Hex H H CH 1 2-Cl—Ph 108.5 ˜ 109.0 (standing*5)
    11 2 n-Hex n-Hex H H CH 1 4-Cl—Ph 150.0 ˜ 151.0 (standing*5)
    12 2 n-Hex n-Hex H H CH 1 2-Br—Ph 115.5 ˜ 116.5 (standing*5)
    13 2 n-Hex n-Hex H H CH 1 4-Me—Ph 145.0 ˜ 146.0 (IPE)
    14 2 n-Hex n-Hex H H CH 1 2-MeO—Ph 99.0 ˜ 100.0 (standing*5)
    15 2 n-Hex n-Hex H H CH 1 3-MeO—Ph 107.5 ˜ 108.0 (standing*5)
  • [0041]
    TABLE 2
    Figure US20020049323A1-20020425-C00009
    Comp.*1 Exp.*2 m.p. (Recry.sol.*3)
    No. No. R1 R2 X1 X2 Y n Ar (° C.)
    16 2 n-Hex n-Hex H H CH 1 2,5-(MeO)2—Ph 124.0 ˜ 124.5 (standing *4)
    17 2 n-Hex n-Hex H H CH 1 3,5-(MeO)2—Ph 94.5 ˜ 95.5 (standing *4)
    18 2 n-Hex n-Hex H H CH 1 2-Py 98.5 ˜ 99.0 (AcOEt)
    19 2 n-Hex n-Hex H H CH 1 3-Py 123.0 ˜ 123.5 (AcOEt)
    20 2 n-Hex n-Hex H H CH 1 4-Py 107.5 ˜ 108.0 (AcOEt)
    21 2 n-Hex n-Hex H H CH 2 Ph 75.0 ˜ 77.0 (Hex)
    22 1 n-Hex n-Hex 6-Cl H CH 1 Ph 145.0 ˜ 146.0 (AcOEt/Hex)
    23 1 n-Hex n-Hex 7-Cl H CH 1 Ph 119.0 ˜ 119.5 (AcOEt/Hex)
    24 1 n-Hex n-Hex OCH2O*5 CH 1 Ph 123.0 ˜ 124.0 (AcOEt/Hex)
    25 1 n-Hex n-Hex 6-OMe 7-OMe CH 1 Ph 122.5 ˜ 123.5 (AcOEt/Hex)
    26 3 n-Hex n-Hex H H COH 1 Ph 106.0 ˜ 108.0 (standing*4)
    27 1 n-Hex n-Hex H H N 1 Ph 53.5 ˜ 55.5 (Hex)
  • Experiment [MDR Receptor Binding Assay][0042]
  • Crude mitochondria fractions prepared from rat cerebral cortex were used as a receptor sample, and [[0043] 3H]PK11195 was used as a [3H]-labeled ligand.
  • A binding assay using the [[0044] 3H]-labeled ligand was carried out according to the following method as described in Journal of Pharmacology and Experimental Therapeutics, 262, 971(1992).
  • Preparation of Receptor Sample: Rat cerebral cortex was homogenized using a Teflon-coated homogenizer in a 10 mM HEPES buffer (pH 7.4) containing 0.32 M sucrose in ten volumes of the wet weight. The homogenate was centrifuged at 900× g for 10 minutes, and the resulting supernatant was centrifuged at 9,000× g for 10 minutes. The precipitate was suspended in a HEPES buffer to give a protein concentration of 1 mg/ml, and centrifuged at 12,000× g for 10 minutes. The resulting precipitate was suspended in a 50 mM HEPES buffer (pH 7.4) to give a crude mitochondria fraction. [0045]
  • MDR Binding Assay: Mitochondria sample (1.0 mg protein/ml), [[0046] 3H]PK11195 (2 nM) and the test drug were reacted at 4° C. for 90 minutes.
  • After completion of the reaction, the reaction mixture was filtered with suction through a glass filter (GF/B) treated with 0.3% polyethyleneimine, and the radioactivity on the filter was measured by a liquid scintillation spectrometer. [0047]
  • The binding at the reaction in the presence of 10 μM PK11195 was defined as non-specific binding of [[0048] 3H]PK11195, and the difference between total binding and non-specific binding was defined as specific binding. A fixed concentration of [3H]PK11195 (2 nM) was reacted with varied concentrations of the test drug under the above-mentioned conditions to give an inhibition curve, and the concentration (IC50) of the test drug to exhibit 50% inhibition of [3H]PK11195 binding was measured by the inhibition curve, and results are shown in Table 3.
    TABLE 3
    Compound No. MDR IC50 (nM)
    04 1.71
    05 0.159
    06 53.4
    18 0.404
    19 0.368
    20 0.192
    21 6.58
    23 0.132

Claims (2)

1. A 1,2-dihydro-2-oxoquinoline compound represented by the formula:
Figure US20020049323A1-20020425-C00010
wherein Ar is a pyridyl group or a group represented by the formula:
Figure US20020049323A1-20020425-C00011
(wherein X3 and X4 are the same or different, and are each a hydrogen atom, a halogen atom, a C1-5 alkyl group, a C1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom, R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom, or X1 and X2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof.
2. A 1,2-dihydro-2-oxoquinoline compound represented by the formula:
Figure US20020049323A1-20020425-C00012
wherein Ar is a pyridyl group or a group represented by the formula:
Figure US20020049323A1-20020425-C00013
(wherein X3 and X4 are the same or different, and are each a hydrogen atom, a halogen atom, a C1-5 alkyl group, a C1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom, R1 and R2 are the same or different, and are each a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom, or X1 and X2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof.
US09/829,203 1997-12-03 2001-04-10 1,2-dihydro-2-oxoquinoline derivatives Expired - Fee Related US6380384B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/829,203 US6380384B1 (en) 1997-12-03 2001-04-10 1,2-dihydro-2-oxoquinoline derivatives

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP332539/1997 1997-12-03
JP9-332539 1997-12-03
JP33253997 1997-12-03
US09/555,568 US6329525B1 (en) 1997-12-03 1998-12-03 1,2-Dihydro-2-oxoquinoline derivatives
US09/829,203 US6380384B1 (en) 1997-12-03 2001-04-10 1,2-dihydro-2-oxoquinoline derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/555,568 Division US6329525B1 (en) 1997-12-03 1998-12-03 1,2-Dihydro-2-oxoquinoline derivatives

Publications (2)

Publication Number Publication Date
US20020049323A1 true US20020049323A1 (en) 2002-04-25
US6380384B1 US6380384B1 (en) 2002-04-30

Family

ID=18256057

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/555,568 Expired - Fee Related US6329525B1 (en) 1997-12-03 1998-12-03 1,2-Dihydro-2-oxoquinoline derivatives
US09/829,203 Expired - Fee Related US6380384B1 (en) 1997-12-03 2001-04-10 1,2-dihydro-2-oxoquinoline derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/555,568 Expired - Fee Related US6329525B1 (en) 1997-12-03 1998-12-03 1,2-Dihydro-2-oxoquinoline derivatives

Country Status (10)

Country Link
US (2) US6329525B1 (en)
EP (1) EP1048655B1 (en)
KR (1) KR20010032667A (en)
CN (1) CN1118456C (en)
AT (1) ATE275133T1 (en)
AU (1) AU736232B2 (en)
CA (1) CA2313055A1 (en)
DE (1) DE69826034T2 (en)
ES (1) ES2227893T3 (en)
WO (1) WO1999028299A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256323A (en) 1999-01-08 2000-09-19 Japan Tobacco Inc 2-oxoquinoline compound and its medicinal use
WO2004103974A1 (en) * 2003-05-23 2004-12-02 Japan Tobacco Inc. Substituted 2-oxoquinoline compound and medicinal use thereof
WO2005021547A2 (en) * 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302323D0 (en) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
WO2008113006A1 (en) * 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
ES2389320T3 (en) 2007-08-01 2012-10-25 Kumiai Chemical Industry Co., Ltd. Oxopyrazine derivative and herbicide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2509728A1 (en) 1981-07-17 1983-01-21 Roussel Uclaf NOVEL QUINOLINE DERIVATIVES, THEIR SALTS, PREPARATION METHOD, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING THE SAME
JPS63146872A (en) 1986-07-08 1988-06-18 Yoshitomi Pharmaceut Ind Ltd Pyrimidinylpiperazine compound
JPH02152966A (en) * 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd 4-hydroxycarbostyril derivative
JP3122671B2 (en) 1990-05-23 2001-01-09 協和醗酵工業株式会社 Heterocyclic compounds
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
US5206382A (en) 1991-06-27 1993-04-27 Fidia Georgetown Institute For The Neurosciences Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders
FR2717175B1 (en) 1994-03-11 1996-06-14 Adir New alkylaminoindane compounds, processes for their preparation and pharmaceutical compositions containing them.
JP3888393B2 (en) 1995-03-10 2007-02-28 大正製薬株式会社 Quinolone derivatives
US6329389B1 (en) 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use

Also Published As

Publication number Publication date
DE69826034T2 (en) 2005-09-08
HK1034074A1 (en) 2001-10-12
ES2227893T3 (en) 2005-04-01
WO1999028299A1 (en) 1999-06-10
EP1048655B1 (en) 2004-09-01
CN1118456C (en) 2003-08-20
AU736232B2 (en) 2001-07-26
KR20010032667A (en) 2001-04-25
EP1048655A4 (en) 2001-04-18
AU1350999A (en) 1999-06-16
CN1280569A (en) 2001-01-17
US6329525B1 (en) 2001-12-11
EP1048655A1 (en) 2000-11-02
CA2313055A1 (en) 1999-06-10
DE69826034D1 (en) 2004-10-07
ATE275133T1 (en) 2004-09-15
US6380384B1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
US6794382B2 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
US4590189A (en) Condensed pyrrolinone derivatives, their production and use
JP2002284699A (en) Remedies for photoreceptor degenerative diseases
US6329525B1 (en) 1,2-Dihydro-2-oxoquinoline derivatives
CA2690079C (en) Sulfonyl-quinoline derivatives
SK42797A3 (en) Pyrido£1,2-a|indoles, process for their production, pharmauceutical compositions containing said substances, intermediate products for their production and their use
CZ200471A3 (en) Purification process of N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide (zaleplon) and zaleplon crystalline forms prepared in such a manner
US6281355B1 (en) Nitrogen-containing tetracyclic compounds
JP4563447B2 (en) 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as GABA receptor ligands for the treatment of anxiety, depression and epilepsy
JPH11236375A (en) 1,2-dihydro-2-oxoquinoline derivatives
JPH11228539A (en) Nitrogen-containing tetracyclic compounds
CN109689650A (en) Substituted N- [2- (4- Phenoxypiperidines -1- base) -2- (1,3- thiazole -5- base) ethyl] benzamide and N- [2- (4- benzyloxy piperidin-1-yl) -2- (1,3- thiazole -5- base) ethyl] heterocyclic carbamate derivatives P2X7 receptor antagonist
HK1034074B (en) 1,2-dihydro-2-oxoquinoline derivatives
JP4129757B2 (en) Arylthioaniline derivatives
MXPA97002445A (en) New pyrimid [1,2-] indo
HK1141009B (en) Sulfonyl-quinoline derivatives
HK1034073B (en) Nitrogen-containing tetracyclic compounds

Legal Events

Date Code Title Description
CC Certificate of correction
REMI Maintenance fee reminder mailed
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20060430

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 20140430